Tratamento dermatológico em dois cães com óleo fitoterápico de andiroba (carapa guianensis) da amazônia, em forma pura e ozonizada: relato de caso

Abstract

This case report evaluated the clinical efficacy of andiroba oil (Carapa guianensis) in its pure and ozonated forms for the topical treatment of mixed infectious dermatopathies in two rescued, sheltered male mixed-breed dogs in the city of Santana, Amapá, Brazil. Complementary examinations including a trichogram, cytology, and skin scraping were requested, which indicated infectious processes caused by Coccus in both and Bacillus in one patient, and Malassezia in the other. The lesions were characterized by erythema, multifocal alopecia, crusts, ulcerations, scaling, and intense pruritus. The therapeutic protocol consisted of topical application every 12 hours for a period of 10 days, with prior local cleaning with saline solution, and the application of the pure oil to the lesions on the animal's left side and ozonated oil to the right side. Clinical monitoring was performed every 3 days (days 0, 3, 6, 10) using standardized forms assessing pruritus, morphological changes, healing, and adverse effects, supplemented by photographic records. By day 3, a significant reduction in pruritus was observed, along with initial closing of ulcerations and attenuation of erythema; by day 6, there was a regression of scaling/crusts, follicular stimulation (telogen to anagen transition), and advanced healing; and by day 10, complete resolution of pruritus was noted in one patient and partial resolution in the other, along with elimination of ectoparasites, follicular repilation, regression of hyperpigmentation, and total absence of adverse effects. There were no significant therapeutic differences between the formulations, although the ozonated oil demonstrated pharmacotechnical superiority with greater viscosity, faster skin absorption, and less residual oiliness. The pure andiroba oil proved to be an accessible, safe, and cost-effective therapy for multifactorial opportunistic dermatopathies, thus validating Amazonian phytotherapy as a viable alternative to conventional pharmacotherapy. Controlled clinical studies are recommended for the standardization of doses and therapeutic protocols.